21. A kit for the implementation of the *in vitro* diagnostic method according to claim 19, comprising:

– a hybrid peptide derived from all or part of the endogenous or exogenous protein, or corresponding to a peptide capable of being recognized by antibodies themselves recognizing the exogenous or endogenous protein,

– reagents to render a medium suitable for the formation of an immunological reaction,

– reagents making it possible to detect the antigen / antibody complex which has been formed as a result of the immunological reaction, the said reagents possibly containing a marker or being capable of being recognized in their turn by a labeled reagent, more particularly in the case where the hybrid peptide or the aforesaid anti-hybrid antibodies are not labeled.

22. A kit for the implementation of the *in vitro* diagnostic method according to claim 20, comprising:

– polyclonal or monoclonal anti-hybrid peptide antibodies, said antibodies being directed against a hybride peptide derived from all or part of the endogenous or exogenous protein,

– reagents to render a medium suitable for the formation of an immunological reaction,

– reagents making it possible to detect the antigen / antibody complex which has been formed as a result of the immunological reaction, the said reagents possibly containing a marker or being capable of being recognized in their turn by a labeled reagent, more particularly in the case where the hybrid peptide or the aforesaid anti-hybrid antibodies are not labeled.

23. A pharmaceutical composition, in particular vaccine, characterized in that it comprises

a hybrid peptide such as defined in one of claim 1, or

an anti-idiotype antibody capable of forming a complex with polyclonal or monoclonal anti-hybrid peptide antibodies such as obtained by immunization of an animal with at least one hybrid peptide defined in claim 1

the said anti-hybrid peptide antibodies being capable of forming a complex with these hybrid peptides, and/or with the peptides or parent proteins corresponding to these

latter, and characterized in that they recognize the parent peptide or the parent protein with an affinity at least equal to that displayed by the anti-parent peptide or anti-parent protein antibodies towards the parent peptide or the parent protein,
such as obtained by immunization of an animal with the said polyclonal or monoclonal anti-hybrid peptide antibodies,
whether or not in combination with a physiologically acceptable vehicle.

24. A pharmaceutical composition characterized in that it comprises
a hybrid peptide such as defined in claim 1,
or an anti-idiotype antibody capable of forming a complex with polyclonal or monoclonal anti-hybrid peptide antibodies such as obtained by immunization of an animal with at least one hybrid peptide defined in claim 1,
the said anti-hybrid peptide antibodies being capable of forming a complex with these hybrid peptides, and/or with the peptides or parent proteins corresponding to these latter, and characterized in that they recognize the parent peptide or the parent protein with an affinity at least equal to that displayed by the anti-parent peptide or anti-parent protein antibodies towards the parent peptide or the parent protein,
such as obtained by immunization of an animal with the said polyclonal or monoclonal anti-hybrid peptide antibodies,
combined with a carrier molecule, whether or not proteic, capable of inducing *in vivo* the production of antibodies neutralizing the exogenous or endogenous protein responsible for the pathology, or inducing *in vivo* a cytotoxic or helper cellular immune response.

25. A pharmaceutical composition, characterized in that it comprises polyclonal or monoclonal anti-hybrid peptide antibodies such as obtained by immunization of an animal with at least one hybrid peptide defined in claim 1, the said antibodies being capable of forming a complex with these hybrid peptides, and/or with the peptides or parent proteins corresponding to these latter, and characterized in that they recognize the parent peptide or the parent protein with an affinity at least equal to that displayed by the anti-parent peptide or anti-parent protein antibodies towards the parent peptide or the parent protein, in combination with a physiologically acceptable vehicle.